Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL

NCT01465334 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

30

Enrollment

OTHER

Sponsor class

Stopped Terminated early due to change in practice.

Conditions

CLL
SLL

Interventions

DRUG: Ofatumumab
DRUG: High-Dose Methylprednisolone
DRUG: Alemtuzumab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]